Company: Aveta Biometrics
CEO: Parag G. Mehta
Website: https://avetabiomics.com/
About Aveta Biometrics
Founded in 2013, Aveta Biomics is a clinical-stage biotechnology company developing groundbreaking oral immunotherapies designed to extend the reach of immunotherapy across immune-cold and immune-hot tumors. APG-157, their first-in-class and patent-protected oral immunotherapy, is entering Phase 3 clinical trial testing. This trial will focus on newly diagnosed head and neck cancer.
In previous trials, APG-157 has had a 100 percent disease control rate, and nearly half of patients experienced reduction in tumor sizes. Backed by compelling clinical data, late-stage development, and world-renowned scientific collaborators, Aveta is building a platform with the potential to redefine cancer immunotherapy.
Want to find out what TechRound can do for your business?
